2026 Top-of-Mind Issues for Life Sciences Companies
Sheppard Mullin has released the 2026 edition of Top-of-Mind Issues for Life Sciences Companies, highlighting key regulatory and innovation trends shaping the industry. As evolving FDA priorities and enforcement approaches take shape under the current administration, shifts in deregulation, safety, and efficacy are influencing product approvals, clinical trials, pricing, and compliance risk. At the same time, rapid advances in AI, digital health, and telehealth are adding new regulatory complexities. The report provides practical insights to help life sciences companies navigate change in 2026.
2026 Top-of-Mind Issues for Life Sciences Companies